Correlation Between Mineralys Therapeutics, and Gracell Biotechnologies

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Gracell Biotechnologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Gracell Biotechnologies into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and Gracell Biotechnologies, you can compare the effects of market volatilities on Mineralys Therapeutics, and Gracell Biotechnologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Gracell Biotechnologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Gracell Biotechnologies.

Diversification Opportunities for Mineralys Therapeutics, and Gracell Biotechnologies

0.58

Correlation Coefficient

Mineralys Therapeutics,  Gracell Biotechnologies

Very weak diversification

The 3 months correlation between Mineralys and Gracell is 0.58. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Gracell Biotechnologies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Gracell Biotechnologies and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Gracell Biotechnologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Gracell Biotechnologies has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Gracell Biotechnologies go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Gracell Biotechnologies

If you would invest  1,195  in Mineralys Therapeutics, Common on August 31, 2024 and sell it today you would earn a total of  116.00  from holding Mineralys Therapeutics, Common or generate 9.71% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	1.59%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  Gracell Biotechnologies

Mineralys Therapeutics,

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Mineralys Therapeutics, unveiled solid returns over the last few months and may actually be approaching a breakup point.

Gracell Biotechnologies

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Gracell Biotechnologies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent fundamental indicators, Gracell Biotechnologies is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors.

Pair Trading with Mineralys Therapeutics, and Gracell Biotechnologies

The main advantage of trading using opposite Mineralys Therapeutics, and Gracell Biotechnologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Gracell Biotechnologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gracell Biotechnologies will offset losses from the drop in Gracell Biotechnologies' long position.

The idea behind Mineralys Therapeutics, Common and Gracell Biotechnologies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.